Exploring Mirum Pharmaceuticals, Inc. (MIRM) Investor Profile: Who’s Buying and Why?

Ever wondered who's investing in Mirum Pharmaceuticals (MIRM) and, more importantly, why? With 402 institutional owners holding a total of 63,876,434 shares, it's clear that big players are watching this biopharmaceutical company closely. In 2024, Mirum reported revenue of $336.89 million, marking an impressive 80.76% increase from the previous year. But who are the major shareholders, and what's driving their interest? Is it the potential of their lead product candidate, LIVMARLI, or the overall growth prospects that have analysts predicting a 51.57% upside with an average price target of $58.55? Dive in to uncover the investor profile of Mirum Pharmaceuticals and the factors influencing their investment decisions.

Mirum Pharmaceuticals, Inc. (MIRM) Who Invests in [Company Name] and Why?

Understanding the investor profile of Mirum Pharmaceuticals, Inc. (MIRM) provides valuable insights into the market's perception of the company and its future prospects. Examining the composition of investors, their motivations, and typical investment strategies can help stakeholders gauge the overall sentiment and potential trajectory of the stock.

Key Investor Types:

Mirum Pharmaceuticals has a mix of different investor types, which include:

• Institutional Investors: These entities, such as mutual funds, hedge funds, and pension funds, constitute a significant portion of MIRM's shareholder base. According to Fintel, institutional investors hold a substantial number of shares. As of April 11, 2025, these institutions collectively held 63,876,434 shares.
• Retail Investors: While institutional investors dominate, retail investors also hold a stake in Mirum Pharmaceuticals.
• Insiders: These include company executives and board members who own shares in the company.

A closer look at the ownership breakdown reveals the following:

• Approximately 65.04% of the company's stock is owned by Institutional Investors
• 9.43% is owned by Insiders
• 11.98% is owned by Public Companies and Individual Investors

Major Shareholders:

The top institutional holders of Mirum Pharmaceuticals include:

• Frazier Life Sciences Management, L.P. with 6,570,392 shares
• Janus Henderson Group Plc with 4,581,642 shares
• BlackRock, Inc. with 3,434,628 shares
• Bvf Inc/Il with 2,796,513 shares
• Eventide Asset Management, Llc with 2,606,938 shares
• Vanguard Group Inc with 2,424,734 shares
• Citadel Advisors Llc with 1,511,183 shares
• Novo Holdings A/S with 1,500,000 shares
• Rock Springs Capital Management LP with 1,471,564 shares

Investment Motivations:

Several factors attract investors to Mirum Pharmaceuticals:

• Growth Prospects: Analysts predict a strong growth trajectory for Mirum Pharmaceuticals. An average annual growth rate of 62% is expected to meet the breakeven date, which is projected to be in approximately 2 years from 2025.
• Revenue Growth: Mirum Pharmaceuticals has demonstrated substantial revenue growth. In 2024, the company's revenue was $336.89 million, reflecting an increase of 80.76% compared to the previous year's $186.37 million.
• Analyst Ratings: The consensus among analysts is a 'Strong Buy' rating for MIRM stock. The average price target is $63.75, which represents a 61.03% increase from the last price of $39.59.
• Strategic Acquisitions: The acquisition of Cholbam and Chenodal from Travere Therapeutics has been viewed as strategically significant, enhancing Mirum's portfolio.
• FDA Approvals: FDA approvals, such as the approval for Ctexli, the first treatment for cerebrotendinous xanthomatosis in the US, and the tablet formulation of LIVMARLI, bolster the company's rare liver disease portfolio.

Investment Strategies:

Investors in Mirum Pharmaceuticals may employ various strategies:

• Long-Term Holding: Many institutional investors, such as Frazier Life Sciences Management and Janus Henderson Group, tend to hold their shares for the long term, indicating confidence in the company's sustained growth.
• Growth Investing: Given the company's high growth prospects and focus on rare diseases, growth investors find Mirum Pharmaceuticals appealing.
• Value Investing: Some investors might view Mirum Pharmaceuticals as undervalued, especially considering its potential to reach profitability by 2027 and its strong revenue growth.

Financial Performance and Outlook:

Mirum Pharmaceuticals has shown promising financial performance:

• Revenue: The company's revenue for 2024 was $336.89 million, an 80.76% increase from 2023.
• Losses: Losses were -$87.94 million, which is 46.18% less than in 2023.
• Analyst Expectations: Analysts expect Mirum Pharmaceuticals to achieve profitability by 2027, with a projected profit of $42 million.
• 2025 Revenue Guidance: The company projects net product sales between $420 million and $435 million for 2025.

Potential Risks:

Despite the positive outlook, there are risks to consider:

• Debt Levels: Mirum Pharmaceuticals has a high debt-to-equity ratio of 137%, which increases investment risk.
• Volatility: The stock has been volatile, with recent technical indicators suggesting a potential downward trend.
• EPS Misses: The Q4 2024 EPS of -$1.85 missed the forecast of -$0.30, though revenue exceeded expectations.

Analyst Ratings and Price Targets:

Analysts have a positive outlook on Mirum Pharmaceuticals:

• The average analyst rating is a 'Strong Buy.'
• The average price target is $63.75, with a high forecast of $74.00 and a low forecast of $53.00.

Recent Stock Performance:

As of April 17, 2025, the stock price of Mirum Pharmaceuticals was $39.10.

For more insights into Mirum Pharmaceuticals, Inc.'s mission, vision, and core values, you can explore: Mission Statement, Vision, & Core Values of Mirum Pharmaceuticals, Inc. (MIRM).

Institutional Ownership Trends:

Examining changes in institutional ownership can provide insights into the shifting sentiment towards Mirum Pharmaceuticals. Recent data indicates:

• Total Institutional Outflows (last 12 months): $156.79M.
• Increased Positions: 116 with 3,587,783 shares.
• Decreased Positions: 3,433,093 shares.
• Held Positions: 46,205,627 shares.
• Total Institutional Shares: 217 with 53,226,503 shares.

Major Transactions:

Significant transactions by major holders include:

Here is a sample of recent transactions by major shareholders:

In summary, Mirum Pharmaceuticals attracts a diverse range of investors, primarily driven by its growth prospects, strategic positioning in the rare disease market, and positive analyst sentiment. While risks such as debt levels and market volatility exist, the company's strong revenue growth and potential for profitability make it an appealing investment for those with a long-term outlook.

Mirum Pharmaceuticals, Inc. (MIRM) Institutional Ownership and Major Shareholders of Mirum Pharmaceuticals, Inc. (MIRM)

Institutional ownership in Mirum Pharmaceuticals, Inc. (MIRM) provides insights into the stability and potential influence on the company's stock. Examining major shareholders and recent changes in their positions can offer a perspective on market sentiment and strategic direction.

As of December 31, 2024, the top institutional holders of Mirum Pharmaceuticals, Inc. (MIRM) include:

• BlackRock Fund Advisors: Holding 2,262,515 shares, representing 4.42% of the company.
• Vanguard Index Funds: Holding 2,209,378 shares, representing 4.31% of the company.
• RA Capital Management, L.P.: Holding 2,050,000 shares, representing 4.00% of the company.
• State Street Global Advisors (US): Holding 1,081,829 shares, representing 2.11% of the company.
• FMR (Fidelity Management & Research): Holding 997,300 shares, representing 1.95% of the company.

These major institutional investors collectively hold a significant percentage of Mirum Pharmaceuticals, Inc. (MIRM)'s outstanding shares, reflecting their confidence in the company's prospects or strategic investment objectives.

Recent changes in ownership among institutional investors can indicate shifts in sentiment and potential impacts on the stock. For example:

• RA Capital Management, L.P.: Increased their holdings by 47.06% in Q4 2024, acquiring an additional 655,000 shares.
• RTW Investments, LP: Decreased their holdings by -44.35% in Q4 2024, selling 700,000 shares.

These changes suggest active portfolio management and varying outlooks on Mirum Pharmaceuticals, Inc. (MIRM)'s future performance. Monitoring these shifts can provide valuable context for investors.

The presence and activities of large institutional investors can significantly influence Mirum Pharmaceuticals, Inc. (MIRM)'s stock price and overall strategy. Their substantial holdings can lead to:

• Price Stability: Large positions can reduce volatility.
• Strategic Influence: Major shareholders may engage with company management regarding strategic decisions.
• Market Confidence: Increased institutional ownership can signal positive market sentiment.

Below is a detailed table summarizing the ownership structure of Mirum Pharmaceuticals, Inc. (MIRM), reflecting data as of December 31, 2024:

Understanding the composition and changes within Mirum Pharmaceuticals, Inc. (MIRM)'s investor base is crucial for assessing market dynamics and potential long-term value. This information helps stakeholders gauge the overall health and attractiveness of the company from an investment perspective.

For more insights into Mirum Pharmaceuticals, Inc. (MIRM)'s strategic direction, explore: Mission Statement, Vision, & Core Values of Mirum Pharmaceuticals, Inc. (MIRM).

Mirum Pharmaceuticals, Inc. (MIRM) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Mirum Pharmaceuticals, Inc. (MIRM) can provide valuable insights into the company’s stability, growth potential, and strategic direction. Examining who is investing, their motivations, and their recent activities offers a glimpse into the market's perception of the company.

Institutional investors often hold a significant portion of Mirum Pharmaceuticals, Inc. (MIRM)'s shares. These investors include:

• Vanguard Group
• BlackRock Fund Advisors
• State Street Global Advisors
• FMR (Fidelity Management & Research)
• RA Capital Management

These firms typically invest based on thorough research and analysis, and their holdings can influence market sentiment. For instance, a large purchase by a well-respected fund might signal confidence in Mirum Pharmaceuticals, Inc. (MIRM)'s prospects, potentially driving up the stock price. Conversely, a significant sell-off could indicate concerns about the company's future performance.

Hedge funds may also hold positions in Mirum Pharmaceuticals, Inc. (MIRM). These funds, known for their aggressive investment strategies, can take large positions and actively engage with company management to influence decisions. Their involvement can sometimes lead to significant strategic shifts or changes in corporate policy aimed at maximizing shareholder value.

Activist investors sometimes target companies like Mirum Pharmaceuticals, Inc. (MIRM) if they believe the company is undervalued or poorly managed. These investors build a significant stake and then publicly advocate for changes, such as:

• Cost-cutting measures
• Restructuring
• Changes in management
• Strategic shifts

Their actions can create both opportunities and risks for other investors, as the outcome of their campaigns is often uncertain.

Monitoring recent moves by key investors can provide valuable signals. For example, a large purchase by an insider (such as a CEO or board member) might suggest strong confidence in the company's future. Conversely, a large sale by a major shareholder could raise concerns.

While specific, real-time data on investor moves is constantly changing, publicly available information like SEC filings (e.g., 13F filings for institutional investors) can provide a snapshot of ownership and recent transactions. Keeping an eye on these filings, along with news reports and analyst commentary, can help investors stay informed about the evolving investor profile of Mirum Pharmaceuticals, Inc. (MIRM) and its potential impact on the company.

For more in-depth information about Mirum Pharmaceuticals, Inc. (MIRM), you might find this resource helpful: Mirum Pharmaceuticals, Inc. (MIRM): History, Ownership, Mission, How It Works & Makes Money

Below is a general illustrative example of institutional ownership based on the latest available data. Note that percentages and share numbers can fluctuate frequently.

Disclaimer: The data provided in the table is based on the most recent information available and may not reflect real-time changes in ownership. These figures are approximate and intended for illustrative purposes only. Investors should consult official SEC filings and financial news sources for the most up-to-date and accurate information.

Mirum Pharmaceuticals, Inc. (MIRM) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to Mirum Pharmaceuticals, Inc. (MIRM) is crucial for assessing the company's current standing and future prospects. Examining the moves of major shareholders, recent market behavior, and analyst perspectives provides a comprehensive view of the forces shaping Mirum's valuation and investor confidence.

Investor sentiment toward Mirum Pharmaceuticals, Inc. (MIRM) can be gauged by observing the trading activity of its major shareholders. Significant increases in holdings by institutional investors often signal a positive outlook, while decreased positions may indicate concerns about the company's performance or future prospects. Analyzing these trends helps to understand the overall confidence level of sophisticated investors.

Recent market reactions to changes in Mirum Pharmaceuticals, Inc. (MIRM)'s ownership structure or large investor moves can provide valuable insights. For instance, a stock price surge following the announcement of a major investment could reflect strong market approval, whereas a decline after a significant sell-off might suggest waning confidence. Monitoring these market reactions helps to quantify the immediate impact of investor decisions on the company's valuation.

Analyst perspectives play a vital role in interpreting the impact of key investors on Mirum Pharmaceuticals, Inc. (MIRM)'s future. Analysts often provide insights into how changes in ownership or investor sentiment might affect the company's strategic direction, financial performance, and long-term growth potential. Their analyses can offer a balanced view, considering both the positive and negative implications of investor activity.

To get a deeper understanding of Mirum Pharmaceuticals, Inc. (MIRM), explore its Mirum Pharmaceuticals, Inc. (MIRM): History, Ownership, Mission, How It Works & Makes Money.

Key aspects of investor sentiment and market impact include:

• Institutional Ownership: Tracking the percentage of shares held by institutions.
• Major Transactions: Identifying significant purchases or sales by large shareholders.
• Market Volatility: Assessing stock price fluctuations in response to investor news.
• Analyst Ratings: Monitoring changes in analyst ratings and price targets.

For example, if a well-known investment firm announces a substantial increase in its stake in Mirum Pharmaceuticals, Inc. (MIRM), this could lead to a positive market reaction, with the stock price potentially increasing due to heightened investor confidence. Conversely, if an influential analyst downgrades the stock based on concerns about future drug approvals or market competition, it could trigger a negative market reaction.

Understanding these dynamics requires a multi-faceted approach, combining the analysis of ownership data, market trends, and expert opinions. This comprehensive view helps stakeholders make informed decisions about Mirum Pharmaceuticals, Inc. (MIRM) and its potential in the pharmaceutical industry.